MindBio Therapeutics

MindBio Therapeutics is a clinical stage drug development company based in Australia, pioneering psychedelic microdosing in multiple Phase 2B clinical trials. Their lead candidate drug, MB22001, is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take-home microdosing, with ongoing Phase 2 clinical trials. These trials include Phase 2B studies in patients with Major Depressive Disorder and those with Late Stage Cancer and Depression. The Phase 2B trial in patients with Major Depressive Disorder aims to evaluate the effectiveness of MB22001 in treating depression. In an open label Phase 2A trial, 53% of patients with depression were in complete remission at week 8. This promising result, with a 60% overall improvement in depressive symptoms, provides confidence for the ongoing Phase 2B trials. Additionally, the Phase 2 clinical trials for cancer patients will assess the feasibility of conducting a randomized controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard treatment, providing initial indications of potential benefits of psychedelic microdosing in advanced cancer. With its innovative approach and promising results, MindBio Therapeutics is positioned as a key player in the pharmaceutical industry. Founded in 2021, the company represents an intriguing investment opportunity due to its pioneering work in mental health research and Phase 1 & 2A trials completion.